everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...919293949596979899100101...132133»
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  Everolimus for Children With Recurrent or Progressive Ependymoma (clinicaltrials.gov) -  May 3, 2018   
    P2,  N=18, Recruiting, 
    Registered November 25, 2009. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Feb 2018 --> Feb 2019
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  May 1, 2018   
    P2,  N=13, Not yet recruiting, 
    Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Dec 2018 Initiation date: Mar 2018 --> Jul 2018
  • ||||||||||  serabelisib (MLN1117) / Takeda
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (clinicaltrials.gov) -  Apr 17, 2018   
    P2,  N=96, Active, not recruiting, 
    N=18 --> 3 | Trial completion date: Jun 2020 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Apr 2018; Study was terminated due to slow, insufficient accrual. Recruiting --> Active, not recruiting | N=189 --> 96 | Trial completion date: Nov 2020 --> Apr 2019 | Trial primary completion date: Mar 2018 --> Oct 2018
  • ||||||||||  everolimus / Generic mfg.
    Journal:  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. (Pubmed Central) -  Apr 13, 2018   
    Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patients with refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut)...The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. (Pubmed Central) -  Apr 13, 2018   
    Surgical guidelines are described in a companion article. In addition to prolonging progression-free survival in patients with pNET, everolimus down-regulates excess production of 2 gastrointestinal hormones, which may help control their associated clinical syndromes.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion:  INPRES: Influence of Exceptional Patient Characteristics on Everolimus Exposure (clinicaltrials.gov) -  Apr 12, 2018   
    P4,  N=56, Completed, 
    In addition to prolonging progression-free survival in patients with pNET, everolimus down-regulates excess production of 2 gastrointestinal hormones, which may help control their associated clinical syndromes. Active, not recruiting --> Completed
  • ||||||||||  everolimus / Generic mfg.
    Trial completion, Trial primary completion date:  Prediction of Everolimus-induced Interstitial Lung Disease (clinicaltrials.gov) -  Apr 12, 2018   
    P=N/A,  N=27, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Oct 2017 --> Jan 2018
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Clinical, Journal:  Clinical practice patterns are relatively uniform between pediatric heart transplant centers: A survey-based assessment. (Pubmed Central) -  Apr 6, 2018   
    Other immunosuppression agents reported were cyclosporine (7/38, 18%), everolimus or sirolimus (3/38, 8%), and azathioprine (2/38, 5%)...In conclusion, we found many similar clinical practice protocols. Most centers are willing to collaborate on a common protocol in order to participate in a RCT and support a trial investigating maintenance immunosuppression.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) -  Apr 6, 2018   
    P3,  N=50, Not yet recruiting, 
    Most centers are willing to collaborate on a common protocol in order to participate in a RCT and support a trial investigating maintenance immunosuppression. Trial completion date: Dec 2020 --> Dec 2022 | Initiation date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2020 --> Aug 2022
  • ||||||||||  everolimus / Generic mfg.
    Trial completion, Trial completion date, Metastases:  Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations (clinicaltrials.gov) -  Apr 6, 2018   
    P2,  N=12, Completed, 
    Trial completion date: Dec 2020 --> Dec 2022 | Initiation date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2020 --> Aug 2022 Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Aug 2017
  • ||||||||||  Votrient (pazopanib) / Novartis, everolimus / Generic mfg., Sutent (sunitinib) / Pfizer
    Journal:  Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. (Pubmed Central) -  Apr 3, 2018   
    The most commonly altered gene was(17%), and alterations in,,, orwere identified in 7% of samples. Responses to treatment with the kinase inhibitors sunitinib, everolimus, and pazopanib are presented in conjunction with tumor genomics.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Trial primary completion date:  Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial (clinicaltrials.gov) -  Apr 3, 2018   
    P2,  N=240, Active, not recruiting, 
    Responses to treatment with the kinase inhibitors sunitinib, everolimus, and pazopanib are presented in conjunction with tumor genomics. Trial completion date: Jan 2019 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2020
  • ||||||||||  Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) -  Apr 3, 2018   
    P1,  N=114, Active, not recruiting, 
    Trial completion date: Jan 2019 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2020 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  lenalidomide / Generic mfg., everolimus / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study of Everolimus (RAD001) in Combination With Lenalidomide (clinicaltrials.gov) -  Mar 19, 2018   
    P1,  N=44, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017
  • ||||||||||  buparlisib (AN2025) / Novartis, Adlai Nortye
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) -  Mar 19, 2018   
    P1,  N=43, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017 Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy, Stroma:  Mesenchymal Stromal Cell Therapy in Renal Recipients (clinicaltrials.gov) -  Mar 16, 2018   
    P2,  N=70, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Trial completion date, Trial primary completion date:  Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer (clinicaltrials.gov) -  Mar 13, 2018   
    P1/2,  N=17, Active, not recruiting, 
    Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019 Trial completion date: May 2019 --> May 2020 | Trial primary completion date: Mar 2018 --> Mar 2019
  • ||||||||||  cisplatin / Generic mfg., everolimus / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin (clinicaltrials.gov) -  Mar 8, 2018   
    P2,  N=39, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jan 2018 --> Jan 2019 | Initiation date: Mar 2016 --> Mar 2016 | Trial primary completion date: Jan 2018 --> Jan 2019
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Kineret (anakinra) / SOBI
    Enrollment closed, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) -  Mar 7, 2018   
    P1,  N=57, Active, not recruiting, 
    Trial completion date: Oct 2016 --> Oct 2018 Recruiting --> Active, not recruiting | N=147 --> 57 | Trial completion date: Jun 2019 --> Jun 2021 | Initiation date: Jun 2012 --> Jun 2012 | Trial primary completion date: Jun 2019 --> Jun 2020